Multimorbidity in SLE: metanalysis of 3 studies (1175 pts) saw Multimorbidity (by higher Charlson comorbidity index/CCI), is a strong independent predictor of mortality in SLE (OR 3.92). In SLE, the most freq comorbidities were DM, CVD, COPD, renal/lung/CNS Dz https://t.co/fuYUdfC6wE

Tramadol not effective at chronic pain The strong opioid painkiller, tramadol, is not that effective at easing chronic pain for which it’s widely prescribed, finds a pooled data analysis of the available research, published online in BMJ Evidence Based Medicine. https://t.co/zFWwyy1j3O

"It is much more important to know what sort of a patient has a disease than what sort of a disease a patient has." – William Osler

Review of GLP-1 agonist use in rheumatology - with benefits beyond DM, obesity, improved survival, reduced major cardiovascular and renal events. Anti-inflammatory & chondroprotective effx shown benefit in knee OA & pain. GLP-1RAs do not prevent gout attacks. More research https://t.co/8zh18mlYDh

FDA has approved nerandomilast (PDE4b inhibitor) for treatment of adults with idiopathic pulmonary fibrosis (IPF). Approval is based on 2 RCTs, FIBRONEER-IPF & FIBRONEER-ILD, that show slowing of lung function decline IP & progressive pulmonary fibrosis (PPF) pts. https://t.co/pIQwyLUBoj

Sequencing DNA to find new lupus treatments MUSC geneticist Betty Tsao, Ph.D., will lead a five-year project to identify rare mutations associated with childhood-onset SLE, or lupus, with more than $3.5 million in funding from the National Institute of Arthritis and https://t.co/1vfQ4fK6FX

Systematic review of obesity management meds - 56 RCTs (60,307 pts). All OMMs were better at total weight loss than PBO (P < 0.0001), >10% semaglutide & tirzepatide (both effective at NIDDM CHF). Semaglutide effective reducing pain in knee osteoarthritis https://t.co/4MX2IiDC2X

Activity Trackers Can Predict RA Flares People with rheumatoid arthritis (RA) who experienced disease flares often showed changes in heart rate and physical activity captured by popular wearable devices 4 weeks before they became clinically apparent, a small study indicated. https://t.co/LjE0LkJTrB

Taiwan study of HBV or HCV reactivation w/ bDMARD use in PsO & PsA - among 5527 treatment episodes (3197 ts/bDMARDs) found a 10% risk of reactivation of HBVr (10.6%) & HCV (9.9%), highest w/ TNFi. Reactivation assoc w/ TNFi, HBsAg+, HBeAg+, immunosuppressant use without antiviral https://t.co/AwpmRpfJUT

NY Times on Osteoporosis in Men The NY Times has addressed the problem of osteoporosis in men noting a need for increased awareness and screening... Read more: https://t.co/SzNtuPllY6 https://t.co/13EcEfv4ab

• NY Times on Osteoporosis in Men | RheumNow

Gender Complexities in Psoriatic Arthritis Treatment Outcomes Analysis of a German psoriatic arthritis (PsA) patients registry demonstrates sex-specific differences regarding clinical manifestation and treatment outcomes, especially with regard to drug discontinuations. https://t.co/zGtfpndod9